Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
2-3-2021

Intestinal Stem Cell Development in the Neonatal Gut: Pathways
Regulating Development and Relevance to Necrotizing
Enterocolitis.
Aparna Venkatraman
Children's Mercy Hospital

Wei Yu
Children's Mercy Hospital

Christopher R. Nitkin
Children's Mercy Hospital

Venkatesh Sampath
Children's Mercy Hospital

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Pediatrics Commons

Recommended Citation
Venkatraman A, Yu W, Nitkin C, Sampath V. Intestinal Stem Cell Development in the Neonatal Gut:
Pathways Regulating Development and Relevance to Necrotizing Enterocolitis. Cells. 2021;10(2):312.
Published 2021 Feb 3. doi:10.3390/cells10020312

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

cells
Review

Intestinal Stem Cell Development in the Neonatal Gut:
Pathways Regulating Development and Relevance to
Necrotizing Enterocolitis
Aparna Venkatraman, Wei Yu, Christopher Nitkin

and Venkatesh Sampath *

Division of Neonatology, Department of Pediatrics, Children’s Mercy Hospital, Kansas City, MO 64108, USA;
avenkatraman@cmh.edu (A.V.); wyu@cmh.edu (W.Y.); crnitkin@cmh.edu (C.N.)
* Correspondence: vsampath@cmh.edu; Tel.: +1-816-234-3591; Fax: +1-816-302-9887



Citation: Venkatraman, A.; Yu, W.;
Nitkin, C.; Sampath, V. Intestinal

Abstract: The intestine is extremely dynamic and the epithelial cells that line the intestine get replaced every 3–5 days by highly proliferative intestinal stem cells (ISCs). The instructions for ISCs
to self-renew or to differentiate come as cues from their surrounding microenvironment or their
niche. A small number of evolutionarily conserved signaling pathways act as a critical regulator
of the stem cells in the adult intestine, and these pathways are well characterized. However, the
mechanisms, nutritional, and environmental signals that help establish the stem cell niche in the
neonatal intestine are less studied. Deciphering the key signaling pathways that regulate the development and maintenance of the stem cells is particularly important to understanding how the intestine
regenerates from necrotizing enterocolitis, a devastating disease in newborn infants characterized
by inflammation, tissues necrosis, and stem cell injury. In this review, we piece together current
knowledge on morphogenetic and immune pathways that regulate intestinal stem cell in neonates
and highlight how the cross talk among these pathways affect tissue regeneration. We further discuss
how these key pathways are perturbed in NEC and review the scientific knowledge relating to
options for stem cell therapy in NEC gleaned from pre-clinical experimental models of NEC.
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The small intestinal tract is a tube-like structure that is critical for the absorption
and digestion of nutrients as well as excretion of waste. Besides being a metabolic organ,
numerous epithelial and non-epithelial cells play an important role in host immunity
acting as a barrier to a multitude of commensal and pathogenic microbiota. The intestine is
composed primarily of three tissue layers. The outer smooth muscle layer together with the
enteric nervous system is responsible for peristalsis. The middle submucosal layer is the
space between the outer muscle and the inner mucosal layer that is filled with stromal cells,
nerve fibers, and various cells of the immune system. The inner mucosal layer consists of a
single layer of epithelium with the lamina propria and basement membrane [1]. The single
layer of intestinal epithelium along with mucin functions as a physical barrier to prevent
the entry of luminal contents into the systemic circulation. This barrier can be disrupted
with intestinal infections, bowel ischemia, or diseases involving severe inflammation such
as necrotizing enterocolitis (NEC) and inflammatory bowel disease [2]. Where the damage
is superficial, the epithelium is quickly repaired by the migration of adjacent cells in
minutes to hours by a process called epithelial restitution [3]. However, in conditions
where the lesions are more severe, intestinal stem cells (ISCs) in the crypt regenerate to
replace the damaged epithelium over several days [4]. In this review, we discuss the
signaling pathways that regulate intestine stem cell function in adults and in neonates. We
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discuss the pathogenesis of the major form of intestinal injury in the neonatal intestine,
NEC, and review the literature with regard to application of stem cell therapy to treat NEC.
2. Intestinal Stem Cells
The intestinal epithelium is a continuously self-renewing tissue which serves a multitude of functions. Through its interaction with its surrounding mesenchyme, cells of
the intestinal epithelium progress though repeated cycles to proliferate, terminally differentiate, and ultimately shed into the intestinal lumen. To fulfill this cellular demand,
the small intestinal epithelium is organized into two spatially distinct units-the crypts of
Lieberkühn which contain highly proliferative ISCs, and the long finger-like projections
called villi which host terminally differentiated cells that are post-mitotic [5]. The intestinal
stem cell (ISCs) resides at the base of crypt, and continuously divide to either self-renew
or give rise to progenitors that differentiate to serve absorptive and secretory function.
Absorptive progenitors differentiate into enterocytes that constitute most of the epithelium,
and mediate nutrient absorption. Secretory progenitors differentiate into goblet cells, tuft
cells, enteroendocrine cells, and Paneth cells. The secretory cells are involved in generation
of mucin, hormones, and antibacterial agents [6]. All the differentiated cells except the
Paneth cells move upwards along the crypt–villus axis and eventually die and slough off
into the lumen. Paneth cells move downwards towards the crypt and are interspersed
between the crypt based columnar cells (CBCs) or ISCs [7].
Physical positioning of the epithelial cells within the crypt have identified two subtypes of ISCs—the first subtype is the active intestinal stem cell called crypt base columnar
cells (CBCs) which frequently divide and thereby contribute to majority of the tissue regeneration. These cells are wedged between Paneth cells and are identified by the marker
leucine rich repeat containing G protein coupled receptor 5 (Lgr5). The second subtype of
ISCs are the quiescent or reserve intestinal stem cells, which are slow dividing ISCs present
in the +4 to +6 position from the base of the crypt. These quiescent ISCs, though resistant
to stress, can be activated when the CBC function is compromised. Several proposed
markers for +4 ISCs include but are not limited to are Bmi, mTert, Hopx, Dclk1, and Lrig [8].
Lineage tracing experiments have revealed that both populations of ISCs can self-renew
and have the ability to give rise to all the lineages of the intestinal epithelium [4,9]. The
ISC function is regulated by both extrinsic and intrinsic factors and have been described in
detail elsewhere [10]. In brief, a gradient of morphogenic factors such as Wingless (Wnt)
and Bone morphogenic protein (BMP) family members dictate ISC function to self-renew or
to differentiate along the crypt–villus axis. In the crypts, Paneth cells and the surrounding
mesenchyme/myo-fibroblasts constitute the niche environment. They generate several
secretory and/or membrane-bound ligands from the Wnt, BMP, and Notch pathways that
tightly regulate ISCs proliferation, maintenance, and differentiation [10,11]. Though the
morphogenetic pathways are very well studied in the adult intestine, information in the
developing neonatal intestine is limited. This review describes the progress so far made
in identifying the developmental pathways that regulate stem cell ontogeny and tissue
morphogenesis in the developing intestine and discuss how these pathways go awry in
disease conditions like necrotizing enterocolitis affecting the neonates.
3. Neonatal Intestinal Ontogeny
In the early embryonic stage, the primitive gut epithelium develops as an undifferentiated pseudostratified layer from the endoderm with surrounding mesenchymal tissues.
During later stages in fetal ontogeny, the epithelium differentiates into a monolayer of
columnar epithelial cells forming villi. Unlike the adult mouse intestine, neonate mouse
lack crypts at birth and the intestine matures postnatally [12]. Fully functional crypts along
with Paneth cells appear two weeks after birth [13,14]. The proliferative epithelium is
restricted to the intervillous region and penetrates the underlying mesenchyme to form
crypts. The formation of the crypt–villus axis within intestinal tissue appears to be regu-
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lated at different levels: extrinsically by paracrine and endocrine signaling, and intrinsically
by transcription factors and cofactors.
4. Paracrine Signaling Regulating Stem Cell Development
At the paracrine level, the cross talk between the surrounding mesenchyme and epithelium induce villus and crypt morphogenesis. The control of intestinal epithelial stem cell
proliferation, differentiation and self-renewal are regulated by developmental pathways,
which are evolutionarily conserved. These include the hedgehog (Hh), Wnt, BMP, and
notch signaling pathways. These pathways overlap between organ morphogenesis and
stem cell biology. Here, we describe the effect of evolutionarily conserved paracellular
signaling on neonatal gut development.
4.1. Hedgehog(Hh) Signaling
Hedgehog signaling involves the binding of Hh ligands like sonic hedgehog (Shh),
Indian hedgehog (Ihh), and Desert hedgehog (Dhh) to their transmembrane receptor
Patched 1 & 2 (Ptch1 & 2) to release the Smoothened (SMO) signal transducer from its
Patched-dependent suppression. SMO stabilizes Gli, the effector of Hh signaling and leads
to Gli-dependent transcriptional activation of target genes [15]. During early development,
the Hh ligands (Shh and Ihh) are expressed in the entire intestinal epithelium and become
progressively restricted to the intervillus region, coinciding with villus morphogenesis.
These ligands send signals to their corresponding receptors, Ptch1 and 2 expressed in
the underlying mesenchyme, and subsequently to their effectors. Perturbation of the Hh
signaling pathway by overexpression of a pan-hedgehog signaling inhibitor, Hedgehoginteracting (HhIP) impairs formation of villi, increases epithelial proliferation, increases
Wnt activity, and decreases epithelial differentiation [16]. In addition, there is abnormal
expansion and localization of the intestinal sub-epithelial myofibroblasts (ISEMF). Thus,
proper patterning of ISEMF is essential for correct organization of the crypt–villus axis.
Partial inhibition of Hh hedgehog signaling leads to abnormally branched villi with ectopic epithelial proliferation and ectopic activation of the Wnt pathway. This feedback
mechanism of mesenchymal cells back to the epithelium is one of the finest examples of
epithelial-mesenchymal interactions controlling intestinal organogenesis.
Another example of epithelial mesenchymal interaction leading to organogenesis is
PDGF signaling. Expression of PDGF is predominantly in the intestinal epithelium, while
its corresponding receptor PDGFR is in the mesenchyme. Loss of PDGFα ligand or its
corresponding receptor affects villus morphogenesis and depletes surrounding PDGFR+
mesenchymal cells but does not affect epithelial proliferation or differentiation [17]. It is
likely that Hh and PDGF signaling cooperate for mesenchymal remodeling and thereby
regulate proper epithelial patterning. This relay of information from epithelium to mesenchyme and back to epithelium helps in the formation of the functional crypt–villus axis
during postnatal development. Altogether, the hedgehog pathway in neonates play a
key role in demarcating the villus from the crypt by promoting villus morphogenesis and
restricting the proliferating compartment to the intervillus region.
4.2. BMP Signaling
As members of the TGF-β superfamily, BMPs traffic signaling between mesenchyme
and epithelium. BMP signaling is initiated by binding of BMPs to their corresponding
receptors—the most prevalent of which are type I (Ia or Ib) and type II. Binding of ligand
to its corresponding receptor leads to the phosphorylation and translocation of the SMAD
family of transcription factors, a downstream mediator for both TGFs and BMPs, into the
nucleus [18]. These morphogens are important during development as well as in adults.
In the intestine, while BMP ligands BMP2 and BMP4 are expressed in the surrounding
mesenchyme, their corresponding receptor BMPR1a is expressed in intestinal epithelium.
During early development, BMP4 expression is restricted to the intervillus region where
nascent villi are formed [19]. Thus, the presence of phospho-Smad(p-Smad), an indicator

Cells 2021, 10, 312

4 of 17

of BMP activity, is seen mostly in the villus. Interestingly, the BMP antagonist noggin
expression surrounds the base of the crypt. Taken together, the presence of BMP signaling
inhibitor, Noggin, at the crypt base and BMP signaling activator/transducer, p-Smad, in
the villi demonstrate a gradient of BMP signaling along the crypt–villus axis, with high
BMP activity in the villus and low BMP activity near the crypt.
Germline mutations in SMAD4 and BMPR1a are frequently found in individuals with
familial Juvenile Polyposis. This condition is characterized by intestinal hamartomatous
polyps comprised of both stromal and epithelial tissue [20,21]. Misexpression of the BMP
inhibitor Noggin driven by the villin promoter in early stages of development results in
enlarged and misshapen villi. Mice lacking noggin show an extensive loss of villi and
ectopic crypt formation and hyperplasia of stroma similar to that of Juvenile Polyposis in
humans [19,22]. Conversely, genetic ablation of the BMP receptor, or the overexpression of
the antagonist noggin leads to development of a large number of crypt-like structures on
the sides of the villi as well as where the crypts are localized [23]. Loss of BMP signaling in
parallel activates Hh and PDGF signaling which could explain hyperplasia of the stroma.
Altogether these studies suggest that, in neonates, BMP signaling plays a key role in villus
morphogenesis, mesenchymal cell proliferation, and prevents ectopic crypt formation by
cooperating with Hh and PDGF pathways.
4.3. Wnt Signaling
Wnt signaling is highly conserved across species and plays an important role in
normal homeostasis and disease pathophysiology during development. Wnt ligands act as
paracrine signaling molecules to initiate downstream signaling that include both canonical
and non-canonical pathways. Canonical Wnt signaling is initiated by binding of Wnt
ligands to their cognate membrane bound receptors the frizzled protein and co-receptor
the LDL receptor-related proteins 5 and 6 (LRP5/6). Formation of this complex results
in nuclear accumulation of β-catenin and subsequent activation of Transcription Factor 7
(TCF) target genes like cMyc. In non-canonical Wnt signaling, binding of Wnt ligands to the
frizzled receptor stimulates downstream intracellular signaling independent of β-catenin,
which influences various downstream pathways including the Ca2+ -NFAT-IFN γ and the
planar cell polarity (PCP) pathways [24–26].
Canonical Wnt signaling ligands (Wnt3,6 & 9b) as well as their corresponding receptors (Frizzled, 5–7 and Lrp5 and 6) are present only in the crypt epithelium, while
members of non-canonical Wnt signaling are present in the Villus epithelium and the
mesenchyme [27]. In the fetal stage and at birth, canonical Wnt signaling activity is evident
only in the villus region. This is supported by several experiments that analyzed Wnt
activity by measuring top-gal activity, nuclear localization of β-catenin, and β galactosidase
staining. By postnatal day 2, Wnt signaling that was pervasively active across the entire
villi during the fetal stage and covered the entire villi gets restricted to the intervillus region
and ultimately to the crypt in adults. Homozygous deletion of TCF4, a key transcriptional
effector of Wnt signaling in both neonates and adults, leads to a complete loss of crypts,
and mice were left with non-dividing differentiated villus cells. This suggests that Wnt
signaling is required for formation of crypts of Lieberkühn [28,29]. Similar results were
obtained when other members of canonical Wnt signaling were perturbed. Ectopic expression of the Wnt ligand inhibitor Dickkopf1 (Dkk1), conditional deletion of β-catenin,
and simultaneous inhibition of Lgr4 and Lgr5 all led to loss of crypts [30,31]. In addition,
strong Wnt inhibition depleted the secretory cells but absorptive enterocytes remained
unaffected. c-Myc, another transcription factor and downstream target of Wnt signaling
follows the same expression pattern as that of nuclear β-catenin localization [32]. Similarly,
conditional loss of c-myc, which is a direct target of the Wnt-β-catenin-TCF pathway,
specifically from the intestinal epithelium of both adult and neonatal mice, was shown to
inhibit crypt formation [33]. In contrast, transgenic expression of R-spondin 1 (R-Spo1), a
strong Wnt activator, resulted in a massive hyperproliferation of intestinal crypts [34,35].
Taken together, these data indicate that Wnt signaling is essential for maintenance of crypt
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proliferation, intestinal stem cell function, and maintenance of secretory cells in neonates
and adults. Loss of Wnt signaling parallels the loss of the crypt, and aberrant activation of
Wnt signaling results in hyperproliferative crypts.
Wnt signaling also controls segregation of villus from crypt cells through Ephrin
and Ephrin receptors. Akin to notch ligands, Ephrin ligands and Ephrin receptors are
membrane bound and communicate with adjacent cells. These ligands and receptors repel
each other and naturally create boundaries. In the neonatal mouse, ephrin B1 is expressed
by the epithelial cells of the villi, and EphB2 and EphB3 by cells of the intervillus pockets.
Genetic deletion of the EphB2 and EphB3 results in the abnormal presence of Paneth cells in
the villus instead of being localized in the crypt. Post-mitotic cells present in the villus start
appearing at the crypt base [36]. Thus, in addition to Wnt signaling regulating proliferation
and differentiation, it also directs proper segregation of cell types in the intestine through
ephrins.
4.4. Notch Signaling
Notch signaling is highly conserved and well recognized for its role in ISC proliferation and differentiation in the adult intestine [37]. Notch signals are transmitted between
adjacent cells, such that Notch activity in one cell can induce distinct functions in a neighboring cell. This helps in establishing cell boundaries to pattern cellular differentiation and
regulate stem cell function [38]. The Notch signaling pathway is highly conserved and
has four well-known Notch receptors (Notch1–4) and 5 ligands (Jagged 1, 2 and Delta like
ligand1, 2, 4) in mammals [39]. In the adult intestine, the role of Notch signaling in the
regulation of intestinal epithelial cell proliferation and differentiation is well established.
Modulation of Notch signals has profound effects on intestinal development. Inhibition of
notch signaling components increases expression of atonal homolog 1 (ATOH1), a transcription factor, coupled with loss of crypt cell proliferation and secretory cell hyperplasia. A
similar phenotype is observed when Atoh1 is transgenically overexpressed in the intestinal
epithelium [40–43]. Conversely, constitutive activation of Notch signals in the neonatal
intestine leads to an increase in the number of dividing cells and a dramatic impairment of
differentiation of all intestinal cell types [44]. Ectopic Notch activation in the embryonic
foregut results in reversible defects in villus morphogenesis and loss of the proliferative
progenitor compartment. Unlike fetal and neonatal stages, ectopic Notch signaling in adult
intestine leads to a bias against secretory fates [45].
Taken together, notch signaling appears to have variable effects at different stages of
development in the intestine. While it predominantly affects proliferation in the fetal stage,
in the neonates, it affects crypt proliferation and differentiation of all cellular lineages.
In the adult intestine, however, it favors the absorptive fate and affects ISC proliferation.
Furthermore, the effects of notch on proliferation requires cooperation with Wnt signaling
molecules likeTCF4, whereas its influence on intestinal differentiation appears independent
of Wnt [46].
5. Endocrine Signaling
Another layer of regulation for intestinal crypt formation is at the endocrine level. This
is reflected in the steep increase in plasma thyroid hormone (T3) levels immediately after
birth. In parallel, levels of the protein arginine methyltransferase 1 (PRMT1), a coactivator
for the Thyroid hormone (TH)receptor, is upregulated strictly in the intervillus region. Lack
of T3 or its receptor leads to a decrease in intestinal epithelial cells and abnormal intestinal
morphology [47,48]. In addition to endocrine and paracrine control, recent studies have
also shed light on the role of transcription factors in the intestinal morphogenesis, which
form the focus of the next sections.
6. Transcription Factors
At the molecular level, the transcriptional repressor B lymphocyte-induced maturation
protein 1 (Blimp1), a downstream target of the BMP/SMAD pathway, regulates intesti-
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nal maturation. Blimp1, which is strongly expressed in the entire intestinal epithelium
throughout the fetal stage, becomes restricted to the intervillus region in neonates, and this
phenomenon coincides with the rise in TH level. This suggests that Blimp1 expression is
reciprocally regulated by Thyroid hormone activity.
Intestinal specific conditional deletion of Blimp1 led to enhanced formation of crypts,
accelerated development of Paneth cells, and increased migration of enterocytes. Altogether, the conditional inactivation of Blimp1 compromises intestine function and survival [49,50]. This underscores the role of Blimp1 in intestinal maturation in neonates.
Downregulation of blimp1 in the intervillus region where the stem cells are localized causes
a concomitant increase in the expression of stem cell markers like Shh andPRMT1 [27,51].
In the adult intestine, the secretory lineage and crypt size is controlled by Wnt and notch
signaling. However, it appears that, in neonates, BMP signaling predominates in this role,
since Blimp1 acts downstream of BMP/SMAD signaling. It is also surprising that, while
the loss of Blimp1 severely compromised intestinal function and mice survival in neonates,
expression of members of Wnt and Notch family remained unaffected.
Sox9, a transcription factor and a downstream target of Wnt signaling, is expressed
throughout the duodenal epithelium as early as embryonic day 13.5 (E13.5) and subsequently restricted to the crypt of the adult intestine. Sox9 represses Cdx2 and Muc2, two
genes involved in epithelial differentiation, implicating it in intestinal stem cell differentiation. Conditional loss of Sox9 in the adult intestinal epithelium also led to increased
proliferation and Paneth cell loss, [52,53]. However, the role of Sox9 in neonates remains
unexplored.
Altogether, these studies illuminate the fact that a plethora of endocrine, paracrine,
and transcription factors orchestrate intestinal morphogenesis from the neonatal stage
to adult. The involvement of factors involved in the process during the neonatal period
declines over time during maturation to adulthood, suggesting that adult stem cells have
unique requirements of factors and cofactors for intestinal stem cell maintenance and
function distinct from what roles that were predominant in neonates.
7. Necrotizing Enterocolitis Pathophysiology
Necrotizing enterocolitis (NEC) is the most common, life-threatening gastrointestinal
emergency in the neonatal period. Mostly afflicting premature infants born at <36 weeks
gestation, the incidence varies between 5 to 10%, with a mortality of 15–30% [54,55]. Clinically, NEC is characterized by abdominal distension, feed intolerance, bloody stools,
thrombocytopenia, and escalating signs of cardiovascular shock in severe cases [54,56].
The classical abdominal radiograph findings of pneumatosis intestinalis (air within the
intestinal wall), portal venous gas, or pneumoperitoneum is highly indicative of the diagnosis [56,57]. The major risk factors for NEC include prematurity, formula feeding,
the combination of anemia and blood transfusions, hypoxic-ischemic events, and clinical
chorioamnionitis [54,55]. Research in the last two decades has highlighted the role of development dysmaturity of the intestinal immune system, aberrant intestinal inflammation,
gut microbiota, and genetics in the causation of NEC [58]. While the final common mechanistic is yet to be elucidated, consensus is emerging that NEC is a phenotype for deviant
activation of intestinal Toll Like Receptor (TLR) signaling that results in a breakdown of
the intestinal barrier, bacterial invasion, pathological intestinal inflammation, and necrosis,
and, in severe cases, cardiopulmonary involvement and shock [54,55,58–60].
7.1. Dysmaturity of the Intestinal Immune System in Preterm Neonates
The premise for a dysmature intestinal immune response in NEC is founded on the
fact that NEC is rare in full term neonates, and occurs in the setting of ischemia related
to congenital heart disease or gastroschisis [60,61]. Data from mice suggest that innate
immune signaling, especially TLR4 signaling is important for crypt development and
intestinal epithelial cell (IEC) differentiation in the fetus [62]. After preterm birth, persistent
IEC TLR4 signaling is potentially pathogenic, as gut bacteria can induce intestinal inflam-
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mation and necrosis through TLR4. In the term neonate, there is a rapid desensitization
of IEC TLR signaling and acquirement of postnatal intestinal tolerance [63–65]. This is
achieved by decreased expression of IRAK1, a key mediator of TLR signaling, increased
expression of inhibitor of kappa B, an inhibitor of NFκB, and localization of TLR receptors
including TLR5, to the basal from the luminal surface of IEC [63–67]. This precise temporal
regulation of IEC TLR signaling during intestinal development highlights the dual role of
TLRs in IEC, i.e., maintaining mucosal homeostasis and IEC function versus contributing
to acute inflammation and necrosis (tolerance vs. intolerance). The concept that there is
imbalance between pro-inflammatory and anti-inflammatory immune signaling in the
preterm intestine is further demonstrated by studies showing that inhibitors of TLR signaling such as SIGIRR, A20, and TOLLIP show reduced expression in preterm intestine [68].
Interestingly, breast milk and probiotics, both of which protect against NEC, upregulate
expression of genes that tamponade TLR4 signaling in the mouse intestine [69–71].
7.2. TLR4 Signaling and NEC Pathogenesis
Human studies on intestinal tissue obtained from infants with NEC show increased
expression of TLR4 and related downstream cytokines and chemokines, while inhibitors
of TLR signaling such as SIGIRR are decreased [69–72]. Furthermore, microbiota studies
show relative abundance of Gram-negative bacteria in preterm infants who develop NEC
implying that aberrant activation of TLRs is central to pathogenesis of human NEC [73,74].
The definitive proof that TLR4 signaling is important for NEC pathogenesis was shown in
mouse models of experimental NEC. C3HeJ mice that lack functional TLR4 signaling are
protected against experimental NEC compared to TLR4 sufficient C3HeN strain mates [75].
Furthermore, IEC-specific deletion of TLR4 was protected against experimental NEC,
demonstrating the critical role for IEC TLR4 signaling in initiating NEC pathogenesis [62].
Fawley et al. [76] showed that mice lacking SIGIRR, a negative regulator of TLR and
Interleukin signaling, had more severe experimental NEC. This is particularly relevant
to human NEC pathogenesis as the loss of function mutations in SIGIRR were enriched
in preterm infants who developed NEC [77]. These data evince that TLR4 activation is
required for NEC in humans, and in experimental NEC animal models (Figure 1).
7.3. Alternate Pathways Involved in NEC
While TLR4 activation is a major mechanism for NEC pathogenesis, investigators
have identified other pathways that are relevant to NEC pathogenesis. Paneth cells lining
the crypt of Lieberkuhn are key components of the innate immune system by secreting
anti-microbial peptides [78,79]. Paneth cell ablation either through genetic targeting or
chemical methods exaggerates NEC in the neonatal intestine [79]. Platelet activating
factor (PAF) has been studied both in humans and mouse models, and contributes to
intestinal inflammation and loss of barrier function seen in NEC [80,81]. In mice, inhibitors
of PAF suppress inflammation and intestinal necrosis seen in experimental NEC [81,82].
Furthermore, in preterm infants with NEC, there is increased PAF expression in intestinal
tissue as well as in the systemic circulation [83]. The interactions between TLR4 activation
and PAF/Paneth signaling in NEC evolution remain yet to be elucidated.
7.4. Role of the Gut Microbiome in Programming NEC Vulnerability
The recent explosion in 16S rRNA sequencing and metagenomics-based studies have
unearthed valuable information on neonatal gut microbial assembly and acquirement of
a dysbiotic gut microbial signature that predisposes to NEC. While this is a vast area of
research, a few points that are pertinent to this review are briefly discussed. Microbial
assembly in the preterm infants is affected by several prenatal factors including maternal diet, presence of intraamniotic infection, and mode of delivery (vaginal vs. cesarean
section) [84–87]. After birth, the major determinants of gut microbial assembly included
type of feeding, i.e., formula feeding vs. breast milk, use of broad-spectrum antibiotics
and the neonatal intensive care environment and practices [84,88–90]. Importantly, in
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comparison with term infants, the preterm infant has decreased diversity, with relative
enrichment of Enterobacteria, and decreases in Bacteroides and Bifidobacteria [73,85,91,92]. In
the preterm infant, infants who develop NEC tend to have increases in Gammaproteobacteria,
a class of Gram-negative bacteria that encompasses many known pathogens implicated
in NEC and sepsis in preterm infants including Enterobacter, Klebsiella, E. coli, and Psuedomonas [73,88,93]. While this is the most consistent pattern of signature associated with
NEC, others have noted decreased bacterial diversity, and both a delay in acquirement
and decreased abundance of Bifidobacteria and Bacteriodes [73,94]. The current concept of
NEC pathogenesis revolves around luminal Gammaproteobacteria penetrating the immature
intestinal barrier in preterm neonates and triggering exaggerated TLR signaling, which
results in the intestinal inflammation and necrosis (Figure 1).

Figure 1. Risk factors and pathogenesis of NEC. Illustration of a healthy villus (left) versus villus
injured in NEC (right). In preterm neonates who do not develop NEC, there is an intact mucin
barrier, gut colonization with symbionts, less pro-inflammatory signaling, and increased expression
in anti-inflammatory genes such as Single Immunoglobulin Interleukin-1 Related Receptor (SIGIRR).
In infants who develop NEC, there is aberrant activation of Toll Like Receptor in association with
increased Gammaproteobacteria, pro-inflammatory signaling, and bacterial translocation accompanied
with reduced mucin barrier. Early studies suggest that, in NEC, Wnt signaling may be reduced
accompanied with the loss of intestinal stem cells. Wnt, Wingless related integration site; BMP, Bone
morphogenetic protein; TLR, Toll-like receptor; NEC, Necrotizing enterocolitis.

7.5. Genetic Susceptibility to NEC in Preterm Neonates
Over the last decade, the contribution of genetic risk factors to NEC susceptibility
has been investigated by several investigators. Genetic risk factors can seek to explain the
inter-individual differences in NEC vulnerability noted in premature infants who have
similar clinical risk factors. Genetic variants in innate immune genes, vascular tone/growth
regulating genes, anti-oxidant response genes, and cytokine/chemokine genes have been
major areas of research [95]. Not surprisingly, one of the strongest genetic signatures
to emerge is around TLR and innate immune genes. The presence of one or more loss
of function NOD2 variants appear to predispose to NEC in one of the largest studies
undertaken in premature infants [96,97]. In addition, using a sequencing based approach,
rare and novel loss of function variants in single immunoglobulin interleukin 1 related
receptor (SIGIRR) that exaggerate TLR4 signaling were enriched in preterm infants who
developed NEC in a pilot study [77]. Interestingly, both NOD2 and SIGIRR are inhibitors
of TLR signaling in the neonatal intestine [93,98]. Genetic variants in the VEGF and other
vascular genes might also be potential loci for NEC vulnerability [99]. Genome-wide
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transcriptome studies in intestinal tissue obtained from preterm infants with and without
NEC also identify innate immune pathways as a key target in NEC [100].
8. Morphogenetic Pathways and NEC
Under normal homeostatic conditions, the epithelial barrier is maintained by an intact
crypt–villus axis. Transit amplifying cells arise from the ISC present in the crypt, migrating
and differentiating along the villus. Finally, enterocytes undergo apoptosis and are shed
into the lumen. This entire process takes 3–5 days. However, in conditions like NEC,
the gut barrier function is impaired, and it is now increasingly recognized that the Toll
like receptor, TLR4, plays a key role in the maintenance of epithelial barrier integrity.
TLR4 is predominantly expressed in the crypt and was found to be colocalized with
LGR5+ ISCs [101]. In both humans with the disease as well as in mouse models of NEC,
there is an increased expression of epithelial TLR4. In mouse models of NEC, activation
of TLR4 signaling increases enterocyte apoptosis and impairs epithelial restitution by
affecting their migration. Activation of TLR4 signaling also led to reduction in epithelial
proliferation suggesting a defect at the stem cell level [102,103]. Mechanistically, TLR4
activation increased intestinal apoptosis via the p53-upregulated modulator of apoptosis
(PUMA). Mice lacking PUMA were not affected, despite having TLR4 activation. TLR-4
activation can also inhibit signaling by β-catenin, a member of the canonical Wnt signaling
pathway, through upregulation of inhibitory kinase GSK3β. In contrast, mutations in
TLR4 or adenoviral-mediated inhibition of TLR4 signaling in neonatal, but not adult, mice
restored β-catenin/Wnt signaling and reduced disease severity, which was attributed to
increased enterocyte proliferation [104]. Transcriptional profiling of ileal samples from an
experimental model of NEC in mice demonstrate a decrease in the Wnt ligand, specifically
Wnt 7b. In addition, accumulation of nuclear β-catenin in the intestinal epithelium was
noted in both mouse models and patient samples. Altogether, it is evident that significant
perturbation of Wnt signaling occurs in NEC [105].
In patients with NEC as well as in the mouse model of NEC, a significant reduction
in the formation of the goblet cell is observed [62]. A lack of goblet cells affect mucin
production and thereby compromise epithelial barrier integrity. This can be influenced by
the notch signaling pathway, which plays a critical role in cell fate decision. Activation of
Notch suppresses goblet cell formation via repressing ATOH1/Math1. In the mouse model
of NEC, enterocyte-specific lack of TLR4 significantly increased goblet cell formation, an
effect mediated through repression of notch signaling. This signaling was found to be
via a Myd88-independent pathway. In addition, inhibition of notch signaling using the
gamma secretase inhibitor DBZ in an animal model of NEC increased goblet cell formation
and reduced severity of NEC, underscoring the importance of notch signaling in NEC
pathophysiology [62].
Taken together, these studies demonstrate that immune signaling cooperates with
morphogenetic pathways like Wnt and notch and contribute towards the development of
NEC. These findings also illuminate differences in the role of TLR4 signaling in the neonate
versus adult intestine (Figure 1). TLR4 is pro-apoptotic and inhibits stem cell proliferation
in neonates, whereas, in adults, it promotes epithelial proliferation. Altogether, an increase
in TLR dependent signals in neonates is central to NEC pathogenesis, while the absence of
TLR signaling impairs epithelial regenerative responses [106] and affects the outcome of
diseases like colitis.
9. Stem Cell Therapy for NEC—Sources and Mechanism of Action
Mesenchymal stem cells (MSCs) were first noted for their ability to regenerate infarcted
myocardium [107], and are defined by their ability to differentiate into chondrocytes,
osteocytes, and adipocytes [108]. Since their discovery, they have been identified in the bone
marrow, adipose tissue, umbilical cord (Wharton’s Jelly), umbilical cord blood, placenta,
and amniotic fluid [109]. Bone marrow-derived MSCs (BM-MSCs) were the first described
MSC and are well-studied [110], but those obtained from the umbilical cord tissue (UC-
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MSCs) or umbilical cord blood (UCB-MSCs) may be a superior source [111]. UC/UCBMSCs can be obtained in large quantities without invasive procedures, and appear to have
greater immunomodulatory potential than BM-MSCs [112].
Contrary to the initial belief, MSCs do not directly become new tissue, but instead
secrete growth factors and cytokines, as well as packaged exosomes and microvesicles containing protein, lipid, and nucleic acids to mediate beneficial effects [113]. Paracrine factors
are key drivers of MSC efficacy; indeed, cell-free preparations are typically as effective as
MSCs themselves [114]. Both MSCs and MSC-derived products act via anti-inflammatory,
pro-angiogenic, anti-fibrotic, and anti-oxidant [115] mechanisms, mediated by factors such
as IL-1β [116], IL-6 [116,117], TNFα [116–118], IFNγ [118], vascular endothelial growth
factor [119], and TGF-β1 [120]. Because of their anti-inflammatory, pro-angiogenic, and
immunomodulatory roles, they have been studied in adult stroke and myocardial ischemia,
as well as sepsis and septic shock [121]. Thus, MSC therapy for NEC is attractive, as
the pathophysiology of NEC includes bacterial infection, inflammation, and ischemia.
There is also a relatively long history of MSC therapy for intestinal inflammatory disease,
with moderate-to-severe Crohn’s Disease being one of the most advanced indications to
date [122].
10. Stem Cell Therapy in Preclinical Models
MSCs for necrotizing enterocolitis (NEC) have been evaluated in animal models for
the last decade, with multiple studies and a recent review [123]. Besner and colleagues
have demonstrated the utility of amniotic fluid-derived MSC, BM-MSC, and neural stem
cells in reducing the incidence of NEC in rats [124,125] with concomitant decreases in
intestinal permeability [126]. Exosomes from these cell types were similarly effective [114,
127], making cell-free therapy a realistic possibility. However, the source of exosomes
is important as differential effects on disease progression have been noted based on the
source. For example, exosomes released from intestinal epithelial cells or immune cells
help in progression of NEC while exosomes derived from MSCs or variable milk source
ameliorate the severity of NEC [128]. Milk-derived exosomes reduce oxidative stress,
decrease cell death, restore goblet cells, muc2 production, and ER function in normal as
well as in experimental NEC [129–133]. MSC-derived exosomes ameliorate the severity
of experimental NEC and preserve gut barrier function in vivo [134]. At present, the
mechanisms behind these diverging outcomes dependent on exosome source is not clear.
Thus, additional studies are warranted to identify the downstream targets activated by
different sources of exosomes.
Synergistic therapy with other novel interventions, such as exogenous heparin-binding
EGF-like growth factor [135] and extracellular vesicles (EVs), also make such therapy more
attractive. Extracellular vesicles (EVs) act as mediators of intercellular signaling via the
delivery of effector molecules. Small intestinal fibroblasts derived EVs carry EGF family
members that are growth factors required for ISC regulation. MSCs or stem cells derived EVs attenuate NEC intestinal injury by endogenous modulation the Wnt/β-catenin
pathway, which may explain their prolonged duration of action despite their rapid clearance [66]. Stem cells derived EVs also stimulate intestinal recovery from NEC by increasing
cellular proliferation, reducing inflammation and ultimately regenerating a normal intestinal epithelium [136]. Since providing niche factors is critical in homeostasis as well
as during regeneration, EVs can serve as novel tools for transporting stem cell factors in
disease conditions like NEC [137]. This may also provide an underpinning to the protective
effect of breast milk, where enteral breast milk exosomes preserve expression of GRP94,
which is upstream of Wnt [138]. Intriguingly, enteral administration of MSC also appears
to be effective, despite the administered product being subject to the digestive process,
and enteral administration of MSC-derived exosomes may also provide an effective and
alternative option for preventing NEC [139]. Modulation of intestinal microbiota dysbiosis,
a key feature of NEC pathogenesis [88], may be an additional mechanism by which MSCs
prevent NEC. Adipose tissue-derived MSCs administered to rats in the cecal ligation and
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puncture model of sepsis reduced the proportion of harmful bacteria and increased the
proportion of beneficial bacteria [140].
Finally, although there are no current clinical trials of MSCs or MSC-derived exosomes
for NEC, an interesting case report for MSC therapy in NEC was published [141]. A 22day old infant born at 37 weeks gestational age developed supraventricular tachycardia
with subsequent NEC involving nearly his entire intestine. Sixty centimeters of bowel
were removed, so the authors recommended a UC-MSC infusion, after which intestinal
blood flow increased. Although this n-of-1 experiment needs to be pursued in larger
trials, this and other trials for other preterm diseases have not reported major adverse
effects. Although there are significant barriers to enrolling neonates in MSC trials [142],
demonstrated safety might facilitate translation of these preclinical findings into clinically
apparent benefits. It is also possible that preterm infants enrolled in MSC trials for other
indications (e.g., bronchopulmonary dysplasia) may be incidentally noted to experience
lower incidence of NEC.
11. Conclusions
The conserved morphogenetic pathways that regulate the maintenance of the stem
cell in the adult intestine, and aid in tissue regeneration during disease are relatively well
characterized compared to the neonatal intestine. Early studies suggest that the intestinal
microbiota, IEC innate immune signaling, and metabolites in the neonatal intestine shape
the development of the intestinal stem cell. Morphogenetic pathways including Wnt,
BMP, Hh, and Notch may have distinct roles in the neonatal intestine, different from that
described in the adult intestine. Understanding how the stem cell is generated, maintained,
and disrupted in diseases such as NEC in the neonatal intestine will enable translating the
power of stem cell therapy to improve outcomes for neonatal diseases.
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